CASI Pharmaceuticals, Inc. (Nasdaq: CASI), is a US pharmaceutical company with a platform to develop and accelerate the launch of innovative therapeutics and pharmaceutical products in China, the US and throughout the world. CASI's product pipeline features (i) CID-103, an anti-CD38 monoclonal antibody being developed for the treatment of hematological cancers; (ii) China regional rights to three US Food and Drug Administration (FDA)-approved drugs (EVOMELA (melphalan hydrochloride for injection), ZEVLIN (ibritumomab tiuxetan) and MARQIBO (vincristine sulfate LIPOSOME injection) and (iii) a portfolio of FDA-approved and pending abbreviated new drug applications (ANDAs). CASI has offices in Rockville, MD and a wholly owned subsidiary in Beijing, China through which substantially all of our business operations are conducted.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):